AP9901582A0 - Combination therapy for musculoskeletal frailty. - Google Patents
Combination therapy for musculoskeletal frailty.Info
- Publication number
- AP9901582A0 AP9901582A0 APAP/P/1999/001582A AP9901582A AP9901582A0 AP 9901582 A0 AP9901582 A0 AP 9901582A0 AP 9901582 A AP9901582 A AP 9901582A AP 9901582 A0 AP9901582 A0 AP 9901582A0
- Authority
- AP
- ARIPO
- Prior art keywords
- compositions
- frailty
- combination therapy
- oxo
- phenyl
- Prior art date
Links
- 208000036119 Frailty Diseases 0.000 title abstract 3
- 206010003549 asthenia Diseases 0.000 title abstract 3
- 238000002648 combination therapy Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 4
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 208000001164 Osteoporotic Fractures Diseases 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 abstract 1
- 229940047889 isobutyramide Drugs 0.000 abstract 1
- GXESHMAMLJKROZ-IAPPQJPRSA-N lasofoxifene Chemical compound C1([C@@H]2[C@@H](C3=CC=C(C=C3CC2)O)C=2C=CC(OCCN3CCCC3)=CC=2)=CC=CC=C1 GXESHMAMLJKROZ-IAPPQJPRSA-N 0.000 abstract 1
- 210000003205 muscle Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physical Education & Sports Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
This invention is directed to pharmaceutical combination compositions and methods containing (-)-cis-6-phenyl-5-(4-(2-pyrrolidin-1-yl-ethoxy)-phenyl)-5,6,7,8-tetrahydronaphthalene-2-ol or a pharmaceutically acceptable salt thereof and 2-amino-n-(2-(3a(r)-benzyl-2-methyl-3-oxo-2,3, 3a, 4,6,7-hexahydor-pyrazolo-[4,3-c]pyridin-5-yl)-1(r)-benzyloxymethyl-2-oxo-ethyl)-isobutyramide or a pharmaceutically acceptable salt thereof, methods of using such compositions and kits containing such compositions. The compositions are useful for treating musculoskeletal frailty, including osteoporosis, osteoporotic fracture, low bone mass, frailty and low muscle mass.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8946998P | 1998-06-16 | 1998-06-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AP9901582A0 true AP9901582A0 (en) | 1999-06-30 |
Family
ID=22217825
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| APAP/P/1999/001582A AP9901582A0 (en) | 1998-06-16 | 1999-06-15 | Combination therapy for musculoskeletal frailty. |
Country Status (30)
| Country | Link |
|---|---|
| EP (1) | EP1087764A1 (en) |
| JP (1) | JP2002518326A (en) |
| KR (1) | KR20010052852A (en) |
| CN (1) | CN1301160A (en) |
| AP (1) | AP9901582A0 (en) |
| AR (1) | AR018869A1 (en) |
| AU (1) | AU4054799A (en) |
| BG (1) | BG105041A (en) |
| BR (1) | BR9911324A (en) |
| CA (1) | CA2335134A1 (en) |
| CO (1) | CO5070587A1 (en) |
| EA (1) | EA200001186A1 (en) |
| GT (1) | GT199900087A (en) |
| HN (1) | HN1999000097A (en) |
| HR (1) | HRP20000859A2 (en) |
| HU (1) | HUP0102505A3 (en) |
| ID (1) | ID27599A (en) |
| IL (1) | IL138630A0 (en) |
| IS (1) | IS5691A (en) |
| MA (1) | MA26652A1 (en) |
| NO (1) | NO20006312D0 (en) |
| OA (1) | OA11505A (en) |
| PA (1) | PA8475901A1 (en) |
| PE (1) | PE20000646A1 (en) |
| PL (1) | PL344981A1 (en) |
| SK (1) | SK18912000A3 (en) |
| TN (1) | TNSN99124A1 (en) |
| TR (1) | TR200003544T2 (en) |
| WO (1) | WO1999065486A1 (en) |
| ZA (1) | ZA993975B (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2360103A1 (en) * | 1999-02-08 | 2000-08-17 | Robert Sladek | Non-human transgenic animal whose germ cells and somatic cells contain a knockout mutation in dna encoding orphan nuclear receptor erralpha |
| DE60124616T2 (en) | 2000-05-08 | 2007-09-13 | Pfizer Products Inc., Groton | Enzymatic cleavage of selective modulators of the estrogen receptor |
| CA2420535A1 (en) * | 2000-08-30 | 2002-03-07 | Mary Tanya Am Ende | Sustained release formulations for growth hormone secretagogues |
| IL145106A0 (en) * | 2000-08-30 | 2002-06-30 | Pfizer Prod Inc | Intermittent administration of a geowth hormone secretagogue |
| US7476653B2 (en) * | 2003-06-18 | 2009-01-13 | Tranzyme Pharma, Inc. | Macrocyclic modulators of the ghrelin receptor |
| WO2006024931A2 (en) * | 2004-08-31 | 2006-03-09 | Pfizer Products Inc. | Therapeutic combinations comprising a selective estrogen receptor modulator and a selective androgen receptor modulator |
| CU23558A1 (en) | 2006-02-28 | 2010-07-20 | Ct Ingenieria Genetica Biotech | COMPOUNDS ANALOG TO THE PEPTIDIC SECRETAGOGS OF THE GROWTH HORMONE |
| ES2602789T3 (en) | 2007-02-09 | 2017-02-22 | Ocera Therapeutics, Inc. | Connector intermediates for the synthesis of macrocyclic modulators of the ghrelin receptor |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA51676C2 (en) * | 1995-11-02 | 2002-12-16 | Пфайзер Інк. | (-)cis-6(S)-phenyl-5(R)-[4-(2-pyrrolidin-I-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol D-tartrate, a method of its preparation, method of THE treatment OF diseases medicated by agonists of estrogen and a pharmaceutical composition |
| TW432073B (en) * | 1995-12-28 | 2001-05-01 | Pfizer | Pyrazolopyridine compounds |
| HN1996000101A (en) * | 1996-02-28 | 1997-06-26 | Inc Pfizer | COMBINED THERAPY FOR OSTEOPOROSIS |
-
1999
- 1999-06-15 PE PE1999000528A patent/PE20000646A1/en not_active Application Discontinuation
- 1999-06-15 AP APAP/P/1999/001582A patent/AP9901582A0/en unknown
- 1999-06-15 HN HN1999000097A patent/HN1999000097A/en unknown
- 1999-06-15 PA PA19998475901A patent/PA8475901A1/en unknown
- 1999-06-15 AR ARP990102848A patent/AR018869A1/en not_active Application Discontinuation
- 1999-06-15 ZA ZA9903975A patent/ZA993975B/en unknown
- 1999-06-16 TN TNTNSN99124A patent/TNSN99124A1/en unknown
- 1999-06-16 EA EA200001186A patent/EA200001186A1/en unknown
- 1999-06-16 CA CA002335134A patent/CA2335134A1/en not_active Abandoned
- 1999-06-16 BR BR9911324-4A patent/BR9911324A/en not_active Application Discontinuation
- 1999-06-16 CO CO99037622A patent/CO5070587A1/en unknown
- 1999-06-16 MA MA25628A patent/MA26652A1/en unknown
- 1999-06-16 KR KR1020007014186A patent/KR20010052852A/en not_active Application Discontinuation
- 1999-06-16 IL IL13863099A patent/IL138630A0/en unknown
- 1999-06-16 TR TR2000/03544T patent/TR200003544T2/en unknown
- 1999-06-16 JP JP2000554366A patent/JP2002518326A/en active Pending
- 1999-06-16 EP EP99923802A patent/EP1087764A1/en not_active Withdrawn
- 1999-06-16 ID IDW20002627A patent/ID27599A/en unknown
- 1999-06-16 SK SK1891-2000A patent/SK18912000A3/en unknown
- 1999-06-16 GT GT199900087A patent/GT199900087A/en unknown
- 1999-06-16 AU AU40547/99A patent/AU4054799A/en not_active Abandoned
- 1999-06-16 WO PCT/IB1999/001117 patent/WO1999065486A1/en not_active Application Discontinuation
- 1999-06-16 CN CN99806237A patent/CN1301160A/en active Pending
- 1999-06-16 HU HU0102505A patent/HUP0102505A3/en unknown
- 1999-06-16 PL PL99344981A patent/PL344981A1/en not_active Application Discontinuation
-
2000
- 2000-10-20 OA OA1200000290A patent/OA11505A/en unknown
- 2000-10-27 IS IS5691A patent/IS5691A/en unknown
- 2000-12-11 BG BG105041A patent/BG105041A/en unknown
- 2000-12-12 NO NO20006312A patent/NO20006312D0/en not_active Application Discontinuation
- 2000-12-14 HR HR20000859A patent/HRP20000859A2/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| HN1999000097A (en) | 1999-11-03 |
| ID27599A (en) | 2001-04-12 |
| CN1301160A (en) | 2001-06-27 |
| EP1087764A1 (en) | 2001-04-04 |
| PE20000646A1 (en) | 2000-08-05 |
| HUP0102505A3 (en) | 2002-12-28 |
| KR20010052852A (en) | 2001-06-25 |
| ZA993975B (en) | 2000-12-15 |
| HRP20000859A2 (en) | 2001-04-30 |
| MA26652A1 (en) | 2004-12-20 |
| NO20006312L (en) | 2000-12-12 |
| OA11505A (en) | 2004-05-07 |
| JP2002518326A (en) | 2002-06-25 |
| AU4054799A (en) | 2000-01-05 |
| PA8475901A1 (en) | 2000-05-24 |
| TNSN99124A1 (en) | 2005-11-10 |
| PL344981A1 (en) | 2001-11-19 |
| IS5691A (en) | 2000-10-27 |
| TR200003544T2 (en) | 2001-04-20 |
| HUP0102505A2 (en) | 2001-11-28 |
| IL138630A0 (en) | 2001-10-31 |
| EA200001186A1 (en) | 2001-06-25 |
| SK18912000A3 (en) | 2001-10-08 |
| AR018869A1 (en) | 2001-12-12 |
| GT199900087A (en) | 2000-12-07 |
| BR9911324A (en) | 2001-04-03 |
| NO20006312D0 (en) | 2000-12-12 |
| CA2335134A1 (en) | 1999-12-23 |
| CO5070587A1 (en) | 2001-08-28 |
| WO1999065486A1 (en) | 1999-12-23 |
| BG105041A (en) | 2001-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT1222195E (en) | NEW COMPOUNDS OF TIAZOLO (4,5-D) PYRIMIDINE | |
| LU91145I2 (en) | FIROCOXIB optionally in the form of a pharmaceutically acceptable salt (PREVICOX). | |
| IL165262A (en) | Kinase inhibitors and pharmaceutical compositions containing them | |
| UA84146C2 (en) | Amides of pyrrolopyridine-2-carboxylic acid as inhibitors of glycogen phosphorylase, method for their synthesis, drug formulation, and their use as therapeutic agents | |
| NO20070837L (en) | Pyrido-pyrido pyrimidine derivatives, their preparation and therapeutic application for the treatment of cancer. | |
| AP9901582A0 (en) | Combination therapy for musculoskeletal frailty. | |
| NO20001515L (en) | Vitronectin receptor antagonist | |
| SE0101322D0 (en) | Novel compounds | |
| AP9901580A0 (en) | Therapeutic combination comprising a selective estrogen receptor modulator and parathyroid hormone. | |
| AP9901581A0 (en) | Therapeutic combinations for musculoskeletal frailty. | |
| ECSP993020A (en) | COMBINATION THERAPY FOR MUSCULOSKELETAL FRAGILITY | |
| CA2274381A1 (en) | Therapeutic combinations comprising a selective estrogen receptor modulator and prostaglandin e2 | |
| ECSP993021A (en) | THERAPEUTIC COMBINATIONS FOR MUSCULOSKELETAL FRAGILITY |